CA1003820A - Steroid compounds - Google Patents
Steroid compoundsInfo
- Publication number
- CA1003820A CA1003820A CA132,814A CA132814A CA1003820A CA 1003820 A CA1003820 A CA 1003820A CA 132814 A CA132814 A CA 132814A CA 1003820 A CA1003820 A CA 1003820A
- Authority
- CA
- Canada
- Prior art keywords
- steroid compounds
- steroid
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- -1 Steroid compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
- C07J3/005—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom the carbon atom being part of a carboxylic function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB278771A GB1384372A (en) | 1971-01-20 | 1971-01-20 | Dereivatives of 17alpha-hydroxyandrost-4-ene-17beta-carboxylic acids |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1003820A true CA1003820A (en) | 1977-01-18 |
Family
ID=9745890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA132,814A Expired CA1003820A (en) | 1971-01-20 | 1972-01-20 | Steroid compounds |
Country Status (17)
Country | Link |
---|---|
JP (1) | JPS5611720B1 (nl) |
AU (1) | AU473868B2 (nl) |
BE (1) | BE778285A (nl) |
CA (1) | CA1003820A (nl) |
CH (1) | CH602786A5 (nl) |
DE (1) | DE2202691A1 (nl) |
DK (1) | DK132894C (nl) |
ES (1) | ES399057A1 (nl) |
FR (1) | FR2122539B1 (nl) |
GB (1) | GB1384372A (nl) |
HK (1) | HK34278A (nl) |
IE (1) | IE36000B1 (nl) |
IL (1) | IL38589A (nl) |
NL (1) | NL172511C (nl) |
NO (1) | NO137321C (nl) |
SE (1) | SE383522B (nl) |
ZA (1) | ZA72401B (nl) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1438940A (en) * | 1972-07-19 | 1976-06-09 | Glaxo Lab Ltd | 17beta-haloalkoxycarbonyl-17alpha-oxysteroids |
DE2365102C2 (de) * | 1973-12-21 | 1982-12-02 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue Pregnansäure-Derivate |
DE2444618C2 (de) * | 1974-09-16 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Neue Pregnan-21-säure-Derivate |
DE2319479C2 (de) * | 1973-04-14 | 1982-10-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Pregnansäure-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate |
GB1514476A (en) * | 1974-08-30 | 1978-06-14 | Glaxo Lab Ltd | Alkyl and haloalkyl androst-4-ene and androsta-1,4-diene-17beta-carboxylates |
SE427276B (sv) * | 1975-04-03 | 1983-03-21 | Hoffmann La Roche | Forfarande for framstellning av d-homosteroider |
CH628355A5 (de) * | 1976-02-24 | 1982-02-26 | Ciba Geigy Ag | Verfahren zur herstellung neuer androstadien-17beta-carbonsaeuren und ihrer ester und salze. |
IT1114534B (it) * | 1978-02-08 | 1986-01-27 | Glaxo Group Ltd | Steroide anti-infiammatorio della serie dell'androstano composizioni che lo contengono e procedimento per produrlo |
CA1138857A (en) * | 1979-01-24 | 1983-01-04 | Leo Alig | D-homosteroids |
SE449106B (sv) * | 1980-07-10 | 1987-04-06 | Otsuka Pharma Co Ltd | Steroid med anti-inflammatorisk verkan samt komposition innehallande denna |
JPS59139315A (ja) * | 1983-01-31 | 1984-08-10 | Taisho Pharmaceut Co Ltd | クリ−ム剤 |
US4607028A (en) * | 1983-08-18 | 1986-08-19 | Ciba-Geigy Corporation | Novel carboxylic acid esters |
US5981517A (en) * | 1996-05-09 | 1999-11-09 | Soft Drugs, Inc. | Androstene derivatives |
GB0015876D0 (en) * | 2000-06-28 | 2000-08-23 | Novartis Ag | Organic compounds |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
BRPI0113042B8 (pt) | 2000-08-05 | 2021-05-25 | Glaxo Group Ltd | composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
BR0209271A (pt) | 2001-04-30 | 2004-06-15 | Glaxo Group Ltd | Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
US7419971B2 (en) | 2003-06-19 | 2008-09-02 | Bodor Nicholas S | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application |
JP4893305B2 (ja) | 2003-06-19 | 2012-03-07 | ボーダー、ニコラス・エス | 局所又は他の局部投与用のソフト抗炎症性ステロイドの活性及び/又は作用持続性の増強 |
GB0316290D0 (en) * | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
US7579335B2 (en) | 2005-01-10 | 2009-08-25 | Glaxo Group Limited | Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions |
US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
US7687484B2 (en) | 2006-05-25 | 2010-03-30 | Bodor Nicholas S | Transporter enhanced corticosteroid activity |
DE102010029875A1 (de) | 2010-06-09 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten |
DE102010029877A1 (de) | 2010-06-09 | 2011-12-15 | Bayer Schering Pharma Aktiengesellschaft | Verfahren zur Herstellung von 1,4-Pregna-diensäure-Derivaten |
US8835410B2 (en) | 2011-05-10 | 2014-09-16 | Bodor Laboratories, Inc. | Treatment of eyelid dermatitis |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3636010A (en) * | 1968-12-23 | 1972-01-18 | Ciba Geigy Corp | Esters of steroid-17-carboxylic acids |
-
1971
- 1971-01-20 GB GB278771A patent/GB1384372A/en not_active Expired
-
1972
- 1972-01-19 IL IL38589A patent/IL38589A/en unknown
- 1972-01-19 NO NO111/72A patent/NO137321C/no unknown
- 1972-01-20 CA CA132,814A patent/CA1003820A/en not_active Expired
- 1972-01-20 AU AU38110/72A patent/AU473868B2/en not_active Expired
- 1972-01-20 ZA ZA720401A patent/ZA72401B/xx unknown
- 1972-01-20 JP JP735572A patent/JPS5611720B1/ja active Pending
- 1972-01-20 FR FR7201852A patent/FR2122539B1/fr not_active Expired
- 1972-01-20 DK DK29672*#A patent/DK132894C/da active
- 1972-01-20 IE IE82/72A patent/IE36000B1/xx unknown
- 1972-01-20 DE DE19722202691 patent/DE2202691A1/de not_active Ceased
- 1972-01-20 CH CH84372A patent/CH602786A5/xx not_active IP Right Cessation
- 1972-01-20 BE BE778285A patent/BE778285A/xx not_active IP Right Cessation
- 1972-01-20 NL NLAANVRAGE7200818,A patent/NL172511C/nl not_active IP Right Cessation
- 1972-01-20 SE SE7200662A patent/SE383522B/xx unknown
- 1972-01-20 ES ES399057A patent/ES399057A1/es not_active Expired
-
1978
- 1978-06-29 HK HK342/78A patent/HK34278A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ZA72401B (en) | 1973-09-26 |
AU3811072A (en) | 1973-07-26 |
BE778285A (fr) | 1972-07-20 |
CH602786A5 (nl) | 1978-08-15 |
IE36000L (en) | 1972-07-20 |
IL38589A (en) | 1976-06-30 |
SE383522B (sv) | 1976-03-15 |
IL38589A0 (en) | 1972-03-28 |
DE2202691A1 (de) | 1972-08-03 |
NL172511B (nl) | 1983-04-18 |
NL7200818A (nl) | 1972-07-24 |
HK34278A (en) | 1978-07-07 |
JPS5611720B1 (nl) | 1981-03-16 |
NO137321B (no) | 1977-10-31 |
DK132894B (da) | 1976-02-23 |
DK132894C (da) | 1976-07-26 |
NO137321C (no) | 1978-02-08 |
AU473868B2 (en) | 1976-07-08 |
FR2122539B1 (nl) | 1975-11-28 |
FR2122539A1 (nl) | 1972-09-01 |
IE36000B1 (en) | 1976-07-21 |
ES399057A1 (es) | 1974-11-01 |
GB1384372A (en) | 1975-02-19 |
NL172511C (nl) | 1983-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU473868B2 (en) | Steroid compounds | |
CA1017336A (en) | Divinyl-diphenyl compounds | |
AU459132B2 (en) | Etrachlorophthalide compounds | |
AU466025B2 (en) | Aminohalopyridyloxy compounds | |
CA1026346A (en) | Triazolyphosphorus compounds | |
CA1006163A (en) | Arylaminopyridine compounds | |
CA981269A (en) | 3-carbamoyl-4-phenyl-quinoline compounds | |
AU466453B2 (en) | Triaszolothienodiazepine compounds | |
CA977345A (en) | Perfluoroalkyl-phosphorus compounds | |
AU464251B2 (en) | Steroid compounds | |
CA955929A (en) | Steroids | |
CA1019871A (en) | Arc- and track - resistant polyepoxide - polysiloxane compounds | |
CA983946A (en) | Disilyl-containing compounds | |
CA1001641A (en) | Polyhalobenzylic disulfooxonium compounds | |
CA989389A (en) | Steroids | |
CA869995A (en) | Steroidal compounds | |
CA879680A (en) | Cyclopropyl-substituted steroids | |
CA869996A (en) | Steroids | |
CA873333A (en) | Steroid derivatives | |
CA880332A (en) | Steroid analogs | |
CA882696A (en) | Styryl-pyrazoline compounds | |
CA889310A (en) | Triazinylaminostilbene compounds | |
CA866216A (en) | Gem-difluoramino compounds | |
CA878508A (en) | N-propargyl-pyridinium compounds | |
CA879704A (en) | Triazinylaminocoumarin compounds |